122 results on '"Lee, Jung-Yun"'
Search Results
2. The efficacy of subsequent chemotherapy in ovarian cancer patients who progressed in prior PARPi
3. A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer
4. DOMENICA study (GINECO-EN105b/ENGOT-en13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1)
5. Impact of clinical trial participation on the survival of patients with newly diagnosed advanced-stage ovarian cancer
6. PD-L1 as the key to survival for the advanced ovarian cancer previously treated with IDS-HIPEC
7. Weekly paclitaxel with pazopanib for heavily treated ovarian cancer
8. Breakthrough of PARP inhibitors resistance treating with the local therapy in recurrent epithelial ovarian cancer patients with oligo-progression
9. Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancer
10. Promising immunotherapeutic strategies based on different immune characteristics of tumor-infiltrating lymphocytes according to molecular classification in endometrial cancer
11. A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
12. Clinical significance of terminally exhausted CD8 T cells in malignant ascites in patients with epithelial ovarian cancer
13. Detection of minimal residual disease using circulating tumor DNA in patients treated with long-term PARP inhibitors maintenance for epithelial ovarian cancer
14. Efficacy and safety of immune checkpoint inhibitor in clear cell ovarian cancer (CCC): the real world data
15. Durvalumab (Durva) plus carboplatin/paclitaxel (CP) followed by durva±olaparib (Ola) as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial
16. Evaluating the usefulness of HIPEC with secondary cytoreductive surgery: did we get the wrong end of the stick?
17. PD-1 blockade improves treatment responses to PARP inhibitors by targeting PD-1+ regulatory T cells in patients with epithelial ovarian cancer
18. Breakthrough of poly(ADP-ribose) polymerase inhibitors (PARPi) resistance treating with the local therapy in recurrent epithelial ovarian cancer patients with oligo-progression
19. Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
20. PD-1 expression level and BRCA1/2 mutations status determine anti-PD-1-induced reinvigoration of tumor-infiltrating CD8 T cells in advanced-stage epithelial ovarian cancer
21. Retrospective study on postoperative pain control using bupivacaine-only injection and bupivacaine with gel injection after single port laparoscopic hysterectomy
22. Ultra-sensitive genomic profiling using deep sequencing of cervical-swab samples in patient with endometrial cancer
23. Mismatch repair deficiency as a predictive biomarker for response to hormone therapy in early-stage endometrial cancer: a Korean Gynecologic Oncology Group study
24. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): a phase II umbrella trial
25. Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: a multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6)
26. Validation of the revised FIGO staging of endometrial cancer: identifying high-risk patients and upstaging them to stage II/article-title>
27. TP017/#812 A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
28. TP003/#1557 An open label, single arm, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16 or 18 positive cervical cancer (DURBAC)
29. PO010/#673 A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
30. TP016/#1542 A multicenter study of niraparib as maintenance therapy in BRCA wild-type, newly diagnosed advanced ovarian cancer (Polo trial)
31. PR061/#869 A retrospective study on the comparison of responsiveness of each chemotherapy for recurrent ovarian cancer after maintenance treatment with PARP inhibitors
32. TP007/#1383 A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)
33. EP015/#747 Prognostic impact of CD73 expression in epithelial ovarian cancer
34. EP264/#775 Genomic alteration before and after progression on first exposure to parp inhibitor (PARPi) among ovarian cancer patients
35. PO007LBA/#1550 Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study
36. PR054/#1517 A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
37. PR003/#357 Peripheral PD-1+regulatory T cells for predicting treatment response to parp inhibitor maintenance in patients with epithelial ovarian cancer
38. EP139/#824 Would preoperative molecular profiling of P53 mutation and mismatch repair deficiency be useful as markers to predict the extent of surgery in early-stage endometrial cancer?
39. 710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
40. EP267/#913 Monitoring of minimal residual disease with circulating tumor DNA in patients with epithelial ovarian cancer on long-term PARP inhibitor maintenance therapy
41. EP266/#907 Relationship of immune-related diabetes mellitus with efficacy of immune checkpoint inhibitors in patients with gynecologic cancers
42. TP011/#1536 A double-blind placebo-controlled phase III chemo-immunotherapy (Paclitaxel-carboplatin-oregovomab [PCO]) vs chemotherapy (Paclitaxel-carboplatin-placebo [PCP]) in patients with newly diagnosed, advanced epithelial ovarian cancer (EOC): FLORA-5/GOG-3035 study
43. PR008/#805 Efficacy and safety of BVAC-C in HPV type 16 or 18 positive cervical carcinoma who failed 1st platinum based chemotherapy: a phase I/IIA study
44. PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)
45. EP269/#163 CD8 and vimentin was associated with overall survival in patients with ovarian cancer treated with intraperitoneal chemotherapy
46. 729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
47. EP272/#891 Impact of clinical trial participation on the survival of patients with newly diagnosed advanced-stage ovarian cancer
48. EP166/#912 Prevalence of paraaortic lymph node metastasis in presumed clinical stage II endometrial cancer
49. #783 Total laparoscopic radical parametrectomy with pelvic lymphadenectomy
50. #800 Could the preoperative status of P53 mutation and mismatch repair deficiency be useful as predictive biomarker for the extent of surgery in early-stage endometrial cancer patients?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.